Source link : https://www.newshealth.biz/health-news/mavacamten-shows-promise-in-heart-failure-with-normal-to-supranormal-ef/
There may be a future for cardiac myosin inhibitors in heart failure with preserved ejection fraction (HFpEF), according to the proof-of-concept EMBARK-HFpEF trial. An established cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM), mavacamten (Camzyos) showed potential for reducing myocardial wall stress and cardiomyocyte injury in 30 HFpEF patients with a left ventricular ejection fraction (LVEF) […]
Author : News Health
Publish date : 2024-09-30 21:28:51
Copyright for syndicated content belongs to the linked Source.
Categories